Quality standard

Quality statement 4: Skin cancer clinical nurse specialist

Quality statement

People with melanoma, high-risk squamous cell carcinoma or a rare skin cancer have access to a skin cancer clinical nurse specialist. [2016, updated 2024]

Rationale

Skin cancer clinical nurse specialists can provide specialist guidance and support at all stages of care and treatment, including follow‑up. They can act as a source of information (including about local support groups) and provide psychological support.

Quality measures

The following measures can be used to assess the quality of care or service provision specified in the statement. They are examples of how the statement can be measured, and can be adapted and used flexibly.

Process

Proportion of people with melanoma, high-risk squamous cell carcinoma or a rare skin cancer who have access to a skin cancer clinical nurse specialist.

Numerator – the number in the denominator who have access to a skin cancer clinical nurse specialist.

Denominator – the number of people with melanoma, high-risk squamous cell carcinoma or a rare skin cancer.

Data source: The National Cancer Patient Experience Survey reports the proportion of respondents with melanoma who had a specialist nurse as a main contact person within the team looking after them who would support them through treatment (Q17). Data for people with high-risk squamous cell carcinoma or a rare skin cancer can be collected from information recorded locally by provider organisations, for example from patient records.

Outcome

a) Quality of life among people with melanoma, high-risk squamous cell carcinoma or a rare skin cancer.

Data source: The Cancer Quality of Life survey reports quality of life reported by people with melanoma, including functional categories for quality of life (EORTC QLQ-C30), overall health (EQ-5D) and summary scores. Data for people with high-risk squamous cell carcinoma or a rare skin cancer can be collected from information recorded locally by provider organisations, for example from patient surveys.

b) Satisfaction with support received from skin cancer clinical nurse specialist, reported by people with melanoma, high-risk squamous cell carcinoma or a rare skin cancer.

Numerator – the number in the denominator who were satisfied with the support received.

Denominator – the number of people with melanoma, high-risk squamous cell carcinoma or a rare skin cancer supported by a skin cancer clinical nurse specialist.

Data source: Data can be collected from information recorded locally by provider organisations, for example from patient satisfaction surveys. The National Cancer Patient Experience Survey includes a number of questions and responses on satisfaction with cancer services by people with melanoma.

What the quality statement means for different audiences

Service providers (such as secondary care services or tertiary care services) ensure that local and specialist skin cancer multidisciplinary teams have a skin cancer clinical nurse specialist to support people with melanoma, high-risk squamous cell carcinoma or a rare skin cancer under their care.

Skin cancer clinical nurse specialists ensure that people with melanoma, high-risk squamous cell carcinoma or a rare skin cancer have access to support at diagnosis and all stages of treatment, particularly at points of transition and follow-up. They provide advice and information about problems or concerns relating to their cancer and signpost to other relevant services, such as local support groups. They may also provide surveillance following treatment for melanoma, high-risk squamous cell carcinoma or a rare skin cancer.

Commissioners ensure that there are enough skin cancer clinical nurse specialists to support all people with melanoma, high-risk squamous cell carcinoma or a rare skin cancer.

People with a type of skin cancer called melanoma, high-risk squamous cell carcinoma or a rare skin cancer have access to a skin cancer clinical nurse specialist who can provide information, advice and support.

Source guidance

Definitions of terms used in this quality statement

Rare skin cancer

Including epidermal and appendage tumours and dermal and subcutaneous tumours. [NICE's guideline on improving outcomes for people with skin tumours including melanoma, appendix 1]

Access to a skin cancer clinical nurse specialist

People with melanoma, high-risk squamous cell carcinoma or a rare skin cancer should be able to access support from a skin cancer clinical nurse specialist. Roles include dermatology, surgery and oncology skin cancer clinical nurse specialists and may encompass nurse consultants and advanced clinical practitioners. Skin cancer clinical nurse specialists provide information and patient advocacy to people with melanoma, high-risk squamous cell carcinoma or a rare skin cancer from the time of diagnosis to treatment periods, points of transition and during follow-up. They provide practical support, such as during the postoperative period, psychosocial support and advise on appropriate referral. They may perform risk factor assessment, holistic needs assessment and personalised care and support planning. They may also carry out skin cancer surveillance and follow-up clinics in parallel with an appropriately trained doctor. [Adapted from NICE's guideline on improving outcomes for people with skin tumours including melanoma, section 3; core membership of the local multidisciplinary team (LSMDT), page 53, the National Cancer Registration and Analysis Service Cancer Outcomes and Services Dataset – Core, data fields for clinical nurse specialist and risk factor assessment, clinical nurse specialist – holistic needs assessment and clinical nurse specialist – personalised care and support planning, and expert opinion]

Equality and diversity considerations

People should be provided with information that they can easily read and understand themselves, or with support, so they can communicate effectively with health and social care services. Information should be in a format that suits their needs and preferences. It should be accessible to people who do not speak or read English, and it should be culturally appropriate and age appropriate. People should have access to an interpreter or advocate if needed. If a need for advocacy is identified, healthcare professionals should allow enough time for the advocate to help the person to prepare before any appointments or discussion and to ensure that they understand the outcome afterwards. People should be supported to use an advocate by healthcare professionals involved in their care, including a skin cancer clinical nurse specialist [Adapted from NICE's guideline on advocacy services for adults with health and social care needs, section 1.5].

For people with additional needs related to a disability, impairment or sensory loss, information should be provided as set out in NHS England's Accessible Information Standard or the equivalent standards for the devolved nations.